TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 23832433
Drug: All groups
Normalized name: All Clear
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: All groups (Curcumin, Fluoxetine, Combination)
Study: 20215935
Drug: Combination therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination therapy (COMB)
Study: 19152106
Drug: Cardiac resynchronization
Normalized name: Leonurus cardiaca extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cardiac resynchronization therapy (CRT) activated (ON)
Study: 19152106
Drug: Cardiac resynchronization
Normalized name: Leonurus cardiaca extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cardiac resynchronization therapy (CRT) inactivated (OFF)
Study: 8036822
Drug: Three vaccine
Normalized name: three-lobe sage extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Three vaccine doses at M0, M1 and M12
Study: 8036822
Drug: One or
Normalized name: Geone Oral Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: One or two doses
Study: 8036822
Drug: Overall vaccination
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Overall vaccination with CHO‐recombinant vaccine
Study: 27221952
Drug: Bedtime hypertension
Normalized name: Buckley's Bedtime Formula
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bedtime hypertension treatment strategy
Study: 27221952
Drug: Bedtime chronotherapy
Normalized name: Buckley's Bedtime Formula
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bedtime chronotherapy with >/=1 conventional hypertension medications
Study: 23782955
Drug: PD 0348292
Normalized name: dolutegravir
DrugBank: Dolutegravir (DB08930)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: PD 0348292 (0.1 mg qd to 10 mg qd)
Study: 23782955
Drug: Enoxaparin (30
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enoxaparin (30 mg bid)
Study: 29688172
Drug: nBDP 100
Approvals — FDA: no, EMA: no, PMDA: no
Description: nBDP 100 μg per nostril twice daily
Study: 27482087
Drug: Intranasally administered
Normalized name: influenza A virus (H1N1) antigen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intranasally administered oxytocin (IN-OT)
Study: 19224304
Drug: Dexamethasone (40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexamethasone (40 mg intravenous)
Study: 17684992
Drug: Perfluorane (4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Perfluorane (4 ml/kg body weight) administered within the first 24 hours after injury
Study: 9815809
Drug: 1, 2,
Normalized name: Pneumococcal 1, 2, 3, 4, 5, 6B, 7F, 8, 9N, 9V, 10A, 11A, 12F, 14, 15B, 17F, 18C, 19A, 19F, 20, 22F, 23F, and 33F vaccine
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1, 2, or 4 mg of aluminum hydroxide-precipitated 3H1 anti-idiotype antibody every other week for four injections and then monthly until tumor progression.
Study: 31645180
Drug: Group reminiscence
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group reminiscence therapy
Study: 3898930
Drug: Ceftriaxone (single
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ceftriaxone (single intramuscular dose)
Study: 2897515
Drug: Rifampicin (four
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rifampicin (four doses in two days)
Study: 30783823
Drug: Telemedicine intervention
Normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Telemedicine intervention (monthly data download from insulin pumps and glucometers, immediate phone feedback, face-to-face visits every 6 months)
Study: 7608354
Drug: Experiential therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Experiential therapy using Gestalt empty‐chair dialogue intervention
Study: 2239758
Drug: Fish diet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fish diet (200 g lean Australian fish flesh/d)
Study: 2239758
Drug: Fish diet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fish diet supplemented with 5 g fish oil/d
Study: 908151
Drug: 1 mg
Normalized name: biotin 1 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 mg oral metoclopramide
Study: 908151
Drug: 5 mg
Normalized name: talc 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 mg oral metoclopramide
Study: 908151
Drug: 10 mg
Normalized name: biotin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg oral metoclopramide
Study: 25477161
Drug: Folate (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Folate (5 mg)
Study: 21176086
Drug: 600 microg
Normalized name: Fentanyl 600 microgram buccal film
Approvals — FDA: no, EMA: no, PMDA: no
Description: 600 microg oral misoprostol (n = 534)
Study: 29588972
Drug: Lacosamide 200
Normalized name: lacosamide 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lacosamide 200 mg/day
Study: 28556284
Drug: α1-blocker monotherapy
Normalized name: Ivy Block
Approvals — FDA: no, EMA: no, PMDA: no
Description: α1-blocker monotherapy
Study: 25790672
Drug: Qiangji Recipe
Normalized name: SALICYLIC ACID 1 g in 100 mL TOPICAL SHAMPOO [Maetria Miracle Recipe PremiumShampoo]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Qiangji Recipe (QR) + Celecoxib Capsule (0.2 g, twice daily)
Study: 25790672
Drug: Celecoxib Capsule
Normalized name: Celecoxib Capsules
DrugBank: Celecoxib (DB00482)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Celecoxib Capsule (0.2 g, twice daily)
Study: 23498169
Drug: Clopidogrel loading
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clopidogrel loading dose (300 mg)
Study: 16030027
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of Anastrozole and Tamoxifen
Study: 12732606
Drug: ACE inhibitors
Normalized name: ACE INHIBITORS
Approvals — FDA: no, EMA: no, PMDA: no
Description: ACE inhibitors and beta‐adrenergic receptor blockers
Study: 7495243
Drug: alpha-tocopherol (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: alpha-tocopherol (50 mg)
Study: 7495243
Drug: beta-carotene (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: beta-carotene (20 mg)
Study: 1705258
Drug: Eight boluses
Normalized name: OC Eight
DrugBank: Benzoyl peroxide (DB09096)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Eight boluses of GH (2 units administered iv)
Study: 1705258
Drug: Constant infusion
Normalized name: constant albicans extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Constant infusion of GH (2 units administered iv)
Study: 1705258
Drug: Constant infusion
Normalized name: constant albicans extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Constant infusion of GH
Study: 6667034
Drug: Lead chelating
Normalized name: lead
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lead chelating agent
Study: 27072591
Drug: Fish oil-enriched
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fish oil-enriched dairy drink (400 mL/day, ±400 mg EPA-DHA/day)
Study: 21636120
Drug: Tiotropium 10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tiotropium 10 μg
Study: 21636120
Drug: Tiotropium 5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tiotropium 5 μg and 10 μg
Study: 19330891
Drug: Antihypertensive medication
Normalized name: ANTIHYPERTENSIVES
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antihypertensive medication supply classification (undersupply, appropriate supply, oversupply)
Study: 19330891
Drug: Medication acquisition
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medication acquisition measures
Study: 16802768
Drug: Fluticasone propionate,
Normalized name: fluticasone propionate, micronized
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluticasone propionate, 88 microg twice daily
Study: 16802768
Drug: Fluticasone propionate,
Normalized name: fluticasone propionate, micronized
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluticasone propionate, 44 microg twice daily
Study: 12954519
Drug: Nordette-28, conventional
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nordette-28, conventional 28-day oral contraceptive (30 microg ethinyl estradiol / 150 microg levonorgestrel)
Study: 10740557
Drug: Remifentanil 0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Remifentanil 0.5 microgram kg‐1 bolus over 30 s and infusion at 0.25 microgram kg‐1 min‐1 without glycopyrolate
Study: 27786012
Drug: Enalapril 20
Normalized name: enalapril 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enalapril 20 and 40 mg o.d.
Study: 29165093
Drug: C. tora
Approvals — FDA: no, EMA: no, PMDA: no
Description: C. tora (330 mg) three times a day
Study: 20109317
Drug: Azelastine nasal
Normalized name: azelastine nasal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Azelastine nasal spray (AZENS)
Study: 17434019
Drug: Levonorgestrel (LNG)
Normalized name: Levonorgestrel
DrugBank: Levonorgestrel (DB00367)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Levonorgestrel (LNG) 1.5 mg administered 3 days before ovulation (Group A)
Study: 17434019
Drug: Levonorgestrel (LNG)
Normalized name: Levonorgestrel
DrugBank: Levonorgestrel (DB00367)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Levonorgestrel (LNG) 1.5 mg administered 1 day before ovulation (Group B)
Study: 7561554
Drug: Rifater supplemented
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rifater supplemented by ethambutol daily for the first 2 months followed by thiacetazone and isoniazid daily for 6 months (2 Rifater EMB/6 HT)
Study: 2293363
Drug: Methylprednisolone infusion
Normalized name: Methylprednisolone
DrugBank: Methylprednisolone (DB00959)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Methylprednisolone infusion during surgery
Study: 28583999
Drug: Placebo (15-minute
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (15-minute loading intravenous infusion followed by a 24-hour maintenance dose)
Study: 21841207
Drug: 500 mg
Normalized name: bran 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 500 mg vernakalant twice daily
Study: 21841207
Drug: 300 mg
Normalized name: rutin 300 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 300 mg vernakalant
Study: 21841207
Drug: 500 mg
Normalized name: bran 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 500 mg vernakalant
Study: 17159764
Drug: Sciatic-femoral block
Normalized name: Ivy Block
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sciatic-femoral block with mepivacaine 1% (15 + 25 mL)
Study: 18335226
Drug: GnRH antagonist
Normalized name: GnRH
DrugBank: Gonadorelin (DB00644)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: GnRH antagonist multidose protocol
Study: 18335226
Drug: Standard long
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard long agonist protocol
Study: 11916358
Drug: Diltiazem treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diltiazem treatment
Study: 8734342
Drug: Meal ingestion
Normalized name: bone meal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Meal ingestion in phase I with an omelette labelled with 99mTc and 150 ml water labelled with 111In
Study: 8734342
Drug: Meal ingestion
Normalized name: bone meal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Meal ingestion in phase II with an omelette labelled with 99mTc and 150 ml water labelled with 111In
Study: 6429677
Drug: Ro 15‐1788
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ro 15‐1788 (5 mg, i.v.)
Study: 24750797
Drug: Probiotic preparation
Normalized name: Rezyst Probiotic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Probiotic preparation (Lactobacillus paracasei ssp.paracasei CRL‐431, Bifidobacterium BB‐12, Streptococcus thermophilus TH‐4, fructooligosaccharide)
Study: 22300834
Drug: 250 g
Normalized name: WORMWOOD OIL 100 g in 250 g TOPICAL GEL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 250 g raw carrots
Study: 22300834
Drug: 250 g
Normalized name: WORMWOOD OIL 100 g in 250 g TOPICAL GEL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 250 g cooked carrots
Study: 15963088
Drug: DP‐b99 (1.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: DP‐b99 (1.0 mg kg(‐1))
Study: 12459663
Drug: Acustimulation with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acustimulation with ReliefBand (2 ml intravenous saline)
Study: 18160741
Drug: Progestogen treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Progestogen treatment
Study: 1775884
Drug: Contraceptive pill
Normalized name: VCF Contraceptive
DrugBank: Nonoxynol-9 (DB06804)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Contraceptive pill treatment
Study: 7008592
Drug: J5 vaccine
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: J5 vaccine
Study: 27491227
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group 2 (20 patients with tubal factors, no treatment)
Study: 11318529
Drug: HMG‐CoA reductase
Approvals — FDA: no, EMA: no, PMDA: no
Description: HMG‐CoA reductase inhibitors (simvastatin and pravastatin)
Study: 3210656
Drug: Not eligible
Approvals — FDA: no, EMA: no, PMDA: no
Description: Not eligible for treatment (maximal supportive care)
Study: 21410420
Drug: Placebo three
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo three times daily for 8 days
Study: 17305253
Drug: Rituximab combination
Normalized name: Rituximab
DrugBank: Rituximab (DB00073)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Rituximab combination therapy
Study: 23250176
Drug: Chlorhexidine solution
Normalized name: CHLORHEXIDINE GLUCONATE 99.0 g in 1 L TOPICAL SOLUTION [CHLORHEXIDINE Solution]
DrugBank: Chlorhexidine (DB00878)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Chlorhexidine solution (0.12%)
Study: 10578803
Drug: Not treated
Approvals — FDA: no, EMA: no, PMDA: no
Description: Not treated with systemic antibiotics
Study: 10578803
Drug: Treated with
Normalized name: Autologous ex vivo expanded cd4+-enriched leukocytes treated with the de-methylating agent 5-aza-deoxycytidine
DrugBank: Autologous ex vivo expanded cd4+-enriched leukocytes treated with the de-methylating agent 5-aza-deoxycytidine (DB19219)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treated with systemic antibiotics
Study: 8916978
Drug: GnRH agonist
Normalized name: GnRH
DrugBank: Gonadorelin (DB00644)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: GnRH agonist therapy with add-back hormone replacement therapy (HRT)
Study: 23715004
Drug: Intranasal steroid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intranasal steroid (INS)
Study: 8273766
Drug: Buprenorphine 2
Normalized name: buprenorphine 2 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Buprenorphine 2 mg/d sublingually
Study: 23598289
Drug: Carbetocin 100
Normalized name: Carbetocin 100 microgram/mL solution for injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Carbetocin 100 μg
Study: 18213374
Drug: Malaria vaccine
Normalized name: malaria vaccine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Malaria vaccine FMP2.1/AS02A (25 microg/0.25 mL or 50 microg/0.5 mL)
Study: 18213374
Drug: Malaria vaccine
Normalized name: malaria vaccine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Malaria vaccine FMP2.1/AS02A (half-dose)
Study: 18213374
Drug: Malaria vaccine
Normalized name: malaria vaccine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Malaria vaccine FMP2.1/AS02A (full-dose)
Study: 20140214
Drug: Rabies vaccine
Normalized name: RABIES VACCINE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rabies vaccine (RabAvert)
Study: 10375153
Drug: High-fidelity assertive
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-fidelity assertive community treatment programs
Study: 8889481
Drug: CC (cool
Approvals — FDA: no, EMA: no, PMDA: no
Description: CC (cool environment)
Study: 1872343
Drug: Clindamycin (450
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clindamycin (450 mg, orally four times daily for 14 days)
Study: 1872343
Drug: Erythromycin (333
Approvals — FDA: no, EMA: no, PMDA: no
Description: Erythromycin (333 mg, orally four times daily for 14 days)
Study: 1872343
Drug: Placebo (orally
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (orally four times daily for 14 days)
Study: 1872343
Drug: Erythromycin (333
Approvals — FDA: no, EMA: no, PMDA: no
Description: Erythromycin (333 mg)
Study: 21921817
Drug: Creatine monohydrate
Normalized name: Creatine Monohydrate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Creatine monohydrate (CM) 20 g·d⁻¹ for 7 days
Study: 21921817
Drug: Placebo (maltodextrin)
Normalized name: Maltodextrin
DrugBank: Maltodextrin (DB12583)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (maltodextrin) 20 g·d⁻¹ for 7 days
Study: 7637681
Drug: Natamycin (suspension,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Natamycin (suspension, lozenges)
Study: 7637681
Drug: Nystatin (suspension)
Normalized name: Nystatin
DrugBank: Nystatin (DB00646)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nystatin (suspension)
Study: 7637681
Drug: Amphotericin B
Normalized name: Amphotericin B
DrugBank: Amphotericin B (DB00681)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Amphotericin B (suspension, lozenges)
Study: 355881
Drug: Therapies labeled
Normalized name: Theraplex Eczema Therapy
DrugBank: Colloidal oatmeal (DB11286)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Therapies labeled as 'no different from control'
Study: 31927774
Drug: Dutasteride 0.5
Normalized name: dutasteride 0.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dutasteride 0.5 mg and Tamsulosin 0.4 mg (DUT-TAM FDC)
Study: 23770335
Drug: Cervarix(®) administered
Normalized name: human papillomavirus type 16, L1 capsid protein (residues 2-471) vaccine / human papillomavirus type 18, L1 capsid protein (residues 2-472) vaccine Prefilled Syringe [Cervarix]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cervarix(®) administered intradermally
Study: 23770335
Drug: Gardasil(®) administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gardasil(®) administered intradermally
Study: 23770335
Drug: Cervarix(®) administered
Normalized name: human papillomavirus type 16, L1 capsid protein (residues 2-471) vaccine / human papillomavirus type 18, L1 capsid protein (residues 2-472) vaccine Prefilled Syringe [Cervarix]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cervarix(®) administered intramuscularly
Study: 23770335
Drug: Gardasil(®) administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gardasil(®) administered intramuscularly
Study: 14563466
Drug: Mud pack
Normalized name: Cream, Multi Ingredient Topical application Cream [3 ROSES FACIAL MUD PACK]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mud pack treatment (15 mm thickness)
Study: 1349493
Drug: Carteolol 10
Normalized name: carteolol 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Carteolol 10 mg
Study: 1349493
Drug: Carteolol 30
Approvals — FDA: no, EMA: no, PMDA: no
Description: Carteolol 30 mg
Study: 1349493
Drug: Carteolol 60
Approvals — FDA: no, EMA: no, PMDA: no
Description: Carteolol 60 mg
Study: 2856892
Drug: Nadolol 40
Normalized name: nadolol 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nadolol 40 mg
Study: 9087975
Drug: Levodopa monotherapy
Normalized name: Levodopa
DrugBank: Levodopa (DB01235)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Levodopa monotherapy
Study: 22976782
Drug: Scaling and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Scaling and root planing (SRP) plus placebo gel
Study: 17335321
Drug: Melatonin (3‐12
Approvals — FDA: no, EMA: no, PMDA: no
Description: Melatonin (3‐12 mg/night; N = 20)
Study: 15461064
Drug: 40 microg
Normalized name: Travoprost 40 microgram/mL eye drops
Approvals — FDA: no, EMA: no, PMDA: no
Description: 40 microg Alprostadil (PGE1) in 250 ml 0.9% saline over 2 hours
Study: 15461064
Drug: 60 microg
Normalized name: Filgrastim 960 microgram/mL solution for injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: 60 microg Alprostadil (PGE1) in 250 ml 0.9% saline over 2 hours
Study: 15461064
Drug: Placebo (250
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (250 ml 0.9% saline solution)
Study: 11559470
Drug: Molecular medicine
Normalized name: Molecular AF
DrugBank: Tolnaftate (DB00525)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Molecular medicine interventions, specific details not provided.
Study: 24265181
Drug: Nebivolol (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nebivolol (10 mg OD)
Study: 21503128
Drug: Periodontal initial
Normalized name: brigatinib
DrugBank: Brigatinib (DB12267)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Periodontal initial therapy (group I)
Study: 21503128
Drug: Non-clinical therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Non-clinical therapy (control group)
Study: 17442688
Drug: Vildagliptin (10-400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vildagliptin (10-400 mg)
Study: 23163959
Drug: Levocetirizine (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Levocetirizine (5 mg/day)
Study: 15196286
Drug: Desloratadine (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Desloratadine (5 mg/day)
Study: 12220477
Drug: Aspirin/ibuprofen hypersensitivity
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aspirin/ibuprofen hypersensitivity
Study: 9635700
Drug: Abdominal radiation
Normalized name: allantoin
DrugBank: Allantoin (DB11100)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Abdominal radiation therapy at 22.5 Gy in 22 fractions (low-dose arm)
Study: 9635700
Drug: Abdominal radiation
Normalized name: allantoin
DrugBank: Allantoin (DB11100)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Abdominal radiation therapy at 27.5 Gy in 27 fractions (high-dose arm)
Study: 7575042
Drug: Different associations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Different associations and galenic forms of medicines (specific details not provided)
Study: 16929992
Drug: 5 mL
Normalized name: WATER,INHL 5 ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 mL of 2% ropivacaine hydrochloride with epinephrine
Study: 16929992
Drug: 5 mL
Normalized name: WATER,INHL 5 ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 mL of 0.9% saline with epinephrine (control)
Study: 11281468
Drug: Combination therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination therapy (isosorbide mononitrate 40 mg and misoprostol 400 microg)
Study: 2520847
Drug: Misoprostol 50
Normalized name: diclofenac-misoprostol 50 mg-200 mcg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Misoprostol 50 mcg
Study: 2512765
Drug: Misoprostol 200
Normalized name: MISOPROSTOL 200MCG TAB
Approvals — FDA: no, EMA: no, PMDA: no
Description: Misoprostol 200 mcg
Study: 2512765
Drug: Misoprostol 400
Normalized name: Misoprostol 400 microgram oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Misoprostol 400 mcg
Study: 22224253
Drug: Rhubarb (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rhubarb (10 g by nasal feeding, 5 g L-glutamine by oral administration, three times per day)
Study: 19615944
Drug: G‐CSF and
Approvals — FDA: no, EMA: no, PMDA: no
Description: G‐CSF and AMD3100
Study: 9223880
Drug: Group F
Normalized name: Prostaglandin group F
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group F (fast; injection speed >= 0.2 ml.s‐1)
Study: 8094648
Drug: Pirenzepine 200
Normalized name: pirenzepine
DrugBank: Pirenzepine (DB00670)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pirenzepine 200 mg
Study: 9404449
Drug: Pyridostigmine 120
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pyridostigmine 120 mg